Evidence map›Paper›PMID 28416287›Full record

ArticleStem cell reports2017

Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications.

Moses Fung, Yan Yuan, Harold Atkins, Qian Shi, Tania Bubela

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Time to publication for results of clinical trials.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Moses FungSchool of Public Health, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB T6G 1C9, Canada; Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.
Yan YuanSchool of Public Health, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB T6G 1C9, Canada.
Harold AtkinsOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Qian ShiSchool of Public Health, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB T6G 1C9, Canada.
Tania BubelaSchool of Public Health, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB T6G 1C9, Canada. Electronic address: tbubela@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the extent to which the publication of clinical trial results of innovative cell-based interventions reflects International Society for Stem Cell Research best practice guidelines. We assessed: (1) characteristics and time to publication of completed trials; (2) quality of reported trials; and (3) results of published trials. We identified and analyzed publications from 1,052 novel stem cell clinical trials: 179 (45.4%) of 393 completed trials had published results; 48 trials were registered by known stem cell tourism clinics, none of which reported results. Completed non-industry-sponsored trials initially published more rapidly, but differences with industry-sponsored trials decreased over time. Most publications reported safety, and 67.3% (mainly early-stage trials) reported positive outcomes. A higher proportion of industry trials reported positive efficacy. Heightened patient expectations for stem cell therapies give rise to ethical obligations for the transparent conduct of clinical trials. Reporting guidelines need to be developed that are specific to early-phase clinical trials.

Indexed as

Practice Guidelines as TopicStem Cell ResearchClinical Trials as TopicHumansPeriodicals as TopicStem Cell Transplantationclinical translationclinical trialclinical trial publicationclinical trial registrystem cellstem cell tourism

Identifiers

PMID28416287
PMCPMC5425617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.